Concepta PLC Concepta announces first myLotus® UK birth (7181R)
31 October 2019 - 6:00PM
UK Regulatory
TIDMCPT
RNS Number : 7181R
Concepta PLC
31 October 2019
RNS release: 31 October 2019
Concepta announces first myLotus(R) UK birth
Concepta PLC (AIM: CPT), the innovative UK personalised
healthcare company and developer of the proprietary self-test
device ("myLotus(R)") the most accurate home-use fertility tracking
and pregnancy testing system available on the U.K. market announces
today the birth of its first baby. Sonny Rocco Gordon was born on
Wednesday 25th September 2019 and Sonny and his mother Isabel
Gordon are both well. This announcement marks another major
milestone for the Company representing its first birth using
myLotus(R), 10 months after its introduction to the UK market. The
Company expects to announce growing numbers of births arising from
other myLotus(R) pregnancies over the coming months.
Isabel Gordon (mother of Sonny Rocco Gordon) said; "Thank you
for bringing us Sonny, without myLotus(R) I am sure he wouldn't be
here... myLotus(R) couldn't have been a better purchase if it
tried. From the moment I came across it on Instagram it just made
so much sense to buy. Having been told it could possibly be a
harder route for me to fall pregnant, I wanted something I could
trust to help me and something which made total sense. myLotus(R)
easily explains all the different features of how to use it, and
the fact that it produces an individualised LH level for each
ovulation test is quite frankly genius. This allowed me to track my
ovulation in such a concise way that I felt in safe hands. The app
is an added bonus which uses your data to inform you when you
should be taking a pregnancy test and stores all your test results
if you ever need to look back over or show your doctor. We fell
pregnant within our first cycle of using myLotus(R) and I feel
passionately that this was purely down to it. My average LH levels
were quite low so only myLotus(R) would have been able to catch my
spike using the numerical factor. The added bonus of myLotus(R) was
the 9 pregnancy tests the pack comes with, which I happily used
every single one to quadruple check I really was pregnant :)"
myLotus(R) the revolutionary home based, self-test product was
launched in the UK in November 2018 to help women trying to
conceive. Early 'trying to conceive' users provided personal video
feedback and testimonials on their menstrual cycle hormone changes
and profile ('signatures') enabling women to better understand and
predict their most fertile days (www.mylotus.com). In March the
Company announced its first supply agreement with Boots UK and in
May its first myLotus pregnancies and user testimonials. More
recently the Company has announced its first collaboration with
Manchester Fertility to advance the clinics Intrauterine
Insemination (IUI) procedures.
myLotus(R) empowers women to self-test their personalised
hormone levels and identify their optimal fertile days thereby
improving their chances of naturally getting pregnant. myLotus(R)
enables women to monitor their fertile phase as part of their
menstrual cycle and is the only home test to 'quantitatively'
measure hormone levels and the 'rate-of-change' preceding ovulation
to help aid a natural or assisted conception. Users measure, record
and track their hormone levels and follow their fertility journey
in an accompanying free downloadable app available in iOS and
Android formats via the www.mylotus.com website.
myLotus(R) is available to women who are planning to start a
family or for those who have previously struggled to naturally
conceive, enabling couples an alternative prior to considering more
costly IVF treatment. The Company expects to release further
hormone health and wellbeing tests to complement its fertility
offering early next year.
Matthew Walls, Chairman said: "We are extremely proud and
delighted to announce our first birth and we send our love and best
wishes to Sonny, Isabel, Joshua and the Gordon family. Todays
announcement is a fabulous achievement for the Company and
continues to strengthen the credibility and awareness of myLotus(R)
amongst women. Our pregnancies are growing in number and we have
waited patiently for our first births. We expect to announce
growing numbers of births arising from myLotus(R) over the coming
months. We will be attending The Fertility Show at Olympia this
weekend and look forward to welcoming those attending to our stand
at C38"
Enquiries
Company: www.conceptaplc.com, Product: www.mylotus.com
Matthew Walls, Chairman
Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin
Tel: +44 (0)20 368 3550
Novum Securities
Colin Rowbury
+44 (0) 20 7399 9400
About Concepta PLC:
Concepta PLC is an AIM-quoted pioneering UK healthcare company
that has developed a proprietary product, myLotus(R), targeted at
the personalised mobile health market with a primary focus on
hormone testing and increasing a woman's chances of naturally
getting pregnant and to provide insight to unexplained
infertility.
myLotus(R) is currently the only consumer product which allows
both quantitative and qualitative home (self-test) test measurement
of a woman's personal luteinizing hormone (LH) during ovulation and
human chorionic gonadotropin (hCG) hormone level during pregnancy,
facilitating higher conception rates and early diagnosis of
fertility issues. The proposition of myLotus(R) is to empower women
to better understand their hormone levels and menstrual cycle and
help women conceive naturally by identifying their window of
fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus(R)
and has launched its first product in the UK. The Company is
preparing plans to roll-out across core EU countries later in
2019.
myLotus(R) is expected to be beneficial to users who have been
unable to conceive after 6 months of trying. This highly motivated
target group of women won't typically be offered medical
intervention until after 12 months of unsuccessfully trying to
conceive, with IVF not usually offered until after two years of
trying to conceive. Research indicates couples start to take
positive action ahead of this time typically with little medical
support to help them do so.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLFFEVIILIVIA
(END) Dow Jones Newswires
October 31, 2019 03:00 ET (07:00 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2024 to May 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From May 2023 to May 2024